Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_3
1
25%
Ph not_applicable
1
25%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
N/A1 (33.3%)

Trials by Status

recruiting125%
unknown125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
recruitingnot_applicable

Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not

NCT07273409
completed

Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy

NCT05005650
unknownphase_3

Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer

NCT05371301
completedphase_2

S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer

NCT00008138

Clinical Trials (4)

Showing 4 of 4 trials
NCT07273409Not Applicable

Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not

Recruiting
NCT05005650

Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy

Completed
NCT05371301Phase 3

Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer

Unknown
NCT00008138Phase 2

S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer

Completed

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4